Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 1 Flow chart of the COBRA-light trial and its extension study

Published byMadeleine Goodman Modified over 6 years ago

Similar presentations

Presentation on theme: "Fig. 1 Flow chart of the COBRA-light trial and its extension study"— Presentation transcript:

1 Fig. 1 Flow chart of the COBRA-light trial and its extension study
From: Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial Rheumatology (Oxford). 2017;56(9): doi: /rheumatology/kex223 Rheumatology (Oxford) | © The Author Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please

2 (A) Disease activity. (B) Physical functioning
(A) Disease activity. (B) Physical functioning. (C) Radiological outcome. (D) Boolean remission. SHS: Sharp–van der Heijde score. From: Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial Rheumatology (Oxford). 2017;56(9): doi: /rheumatology/kex223 Rheumatology (Oxford) | © The Author Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please

3 SHS: Sharp–van der Heijde score.
From: Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial Rheumatology (Oxford). 2017;56(9): doi: /rheumatology/kex223 Rheumatology (Oxford) | © The Author Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please

Download ppt "Fig. 1 Flow chart of the COBRA-light trial and its extension study"

Similar presentations

Fig. 1. Flow diagram of study participants and outcomes.

Fig. 1. Flow diagram of study participants and outcomes.
From: An open day in the metric space

From: An open day in the metric space
Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.
From: Global Banking: Recent Developments and Insights from Research*

From: Global Banking: Recent Developments and Insights from Research*
Fig. 1 Graphical representation

Fig. 1 Graphical representation
Figure 2. CONSORT flow diagram.

Figure 2. CONSORT flow diagram.
From: Political Leadership and Power Redistribution

From: Political Leadership and Power Redistribution
Test characteristics of MRI-detected inflammation for the development of arthritis in CSA patients (A) and RA in UA patients (B) during 1-year follow-up.

Test characteristics of MRI-detected inflammation for the development of arthritis in CSA patients (A) and RA in UA patients (B) during 1-year follow-up.
Error bars represent the mean (s.e.).

Error bars represent the mean (s.e.).
Patients were considered not in MDA (MDA−) with a score of 0, 1, 2, 3 or 4 points and in MDA (MDA+) with a score of 5, 6 or 7 points.

Patients were considered not in MDA (MDA−) with a score of 0, 1, 2, 3 or 4 points and in MDA (MDA+) with a score of 5, 6 or 7 points.
pSS: primary SS; Scl: scleroderma.

pSS: primary SS; Scl: scleroderma.
Figure 3. Examples of tweets classified as ridicule.

Figure 3. Examples of tweets classified as ridicule.
Figure 1. Selection of papers.

Figure 1. Selection of papers.
Fig. 1 Underestimation and lack of sensitivity of T1-weighted fat-suppressed (FS) SPGR sequence in the assessment of BMLs. (A) Sagital T2-weighted.

Fig. 1 Underestimation and lack of sensitivity of T1-weighted fat-suppressed (FS) SPGR sequence in the assessment of BMLs. (A) Sagital T2-weighted.
Fig. 1 Flow chart of study selection

Fig. 1 Flow chart of study selection
Proportion of patients that met the SRI-5 response criteria (A and C) and reasons for non-response (B and D) in trial 1 (A and B) and trial 2 (C and D).

Proportion of patients that met the SRI-5 response criteria (A and C) and reasons for non-response (B and D) in trial 1 (A and B) and trial 2 (C and D).
Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.

Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.
Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser
Fig. 1 Flow of ascertainment of cases with incident childhood IgA vasculitis reported by four sources From: Incidence of IgA vasculitis in children estimated.

Fig. 1 Flow of ascertainment of cases with incident childhood IgA vasculitis reported by four sources From: Incidence of IgA vasculitis in children estimated.
Fig. 1. Geographic locations of Shenzhen and Dongguan

Fig. 1. Geographic locations of Shenzhen and Dongguan

Similar presentations

Ads by Google